Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Paxman

47,00 SEK

+0,43 %

Mindre end 1K følgere

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+0,43 %
-1,05 %
-16,37 %
-14,55 %
-36,83 %
-22,70 %
+30,56 %
+16,63 %
+331,19 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Læs mere
Markedsværdi
1,09 mia. SEK
Aktieomsætning
499,6 t SEK
Omsætning
313,35 mio.
EBIT %
1,36 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
21.5
2026

Delårsrapport Q1'26

22.5
2026

Generalforsamling '26

21.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse2.3.2026, 10.19

Redeye: Paxman (Q4 Review): Quarter below expectations, but IBBM development is encouraging

Paxman
Pressemeddelelse2.3.2026, 07.42

DNB Carnegie Access: Paxman: Closing the chapter on an eventful 2026 – Q4 review

Paxman
Pressemeddelelse27.2.2026, 07.49

DNB Carnegie Access: Paxman: Margin pressure reached its peak – Q4 initial comment

Paxman

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse27.2.2026, 06.00

PAXMAN publishes year-end report as of 31 December 2025

Paxman
Pressemeddelelse23.2.2026, 10.30

Invitation: Live Presentation with CEO Richard Paxman – Year-end report 2025

Paxman
Pressemeddelelse23.2.2026, 09.53

DNB Carnegie Access: Paxman: Category III CPT Codes for Cryocompression secured

Paxman
Pressemeddelelse23.2.2026, 09.13

Redeye: Paxman: CPT-III codes for Paxman’s CIPN device

Paxman
Pressemeddelelse20.2.2026, 15.17

Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy

Paxman
Pressemeddelelse2.2.2026, 17.23

DNB Carnegie Access: Paxman: FX pressure but growth drivers are intact – Q4 preview

Paxman
Pressemeddelelse31.12.2025, 12.50

PAXMAN announces 510k Submission to the U.S. Food and Drug Administration (FDA) for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Paxman
Pressemeddelelse27.11.2025, 16.59

DNB Carnegie Access: Paxman: Key highlights from Capital Markets Day

Paxman
Pressemeddelelse24.11.2025, 18.45

Correction: Further updated Information on OPPS Reimbursement

Paxman
Pressemeddelelse24.11.2025, 17.41

Correction: Updated Information on OPPS Reimbursement

Paxman
Pressemeddelelse24.11.2025, 17.00

DNB Carnegie Access: Paxman: CMS Final Rule landed neutral – long-term story intact

Paxman
Pressemeddelelse24.11.2025, 15.45

Paxman announces that CMS has finalized the 2026 Medicare payment rates for mechanical scalp cooling under the Hospital Outpatient and Physician Fee Schedule.

Paxman
Pressemeddelelse17.11.2025, 13.22

DNB Carnegie Access: Paxman: Margin pressure as expected, outlook still good – Q3 review

Paxman
Pressemeddelelse17.11.2025, 08.28

Redeye: Paxman Q3 (Review) - Softer sales than expected, but outlook remains strong

Paxman
Pressemeddelelse14.11.2025, 07.03

DNB Carnegie Access: Paxman: Meets our expectations on profitability – Q3 initial comment

Paxman
Selskabsmeddelelse14.11.2025, 06.00

PAXMAN publishes its interim report for Q3 2025

Paxman
Pressemeddelelse7.11.2025, 10.15

Invitation: Live Presentation with CEO Richard Paxman – Q3 2025

Paxman
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.